



Universiteit
Leiden
The Netherlands

The sacral chordoma margin

Radaelli, S.; Fossati, P.; Stacchiotti, S.; Akiyama, T.; Asencio, J.M.; Bandiera, S.; ... ; Gronchi, A.

Citation


Radaelli, S., Fossati, P., Stacchiotti, S., Akiyama, T., Asencio, J. M., Bandiera, S., ... Gronchi, A. (2020). The sacral chordoma margin. *European Journal Of Surgical Oncology*, 46(8), 1415-1422. doi:10.1016/j.ejso.2020.04.028

Version: Publisher's Version

License: [Creative Commons CC BY 4.0 license](https://creativecommons.org/licenses/by/4.0/)

Downloaded from: <https://hdl.handle.net/1887/3280404>

Note: To cite this publication please use the final published version (if applicable).



The sacral chordoma margin

S. Radaelli ^{a,*}, P. Fossati ^{b,1}, S. Stacchiotti ^c, T. Akiyama ^d, J.M. Asencio ^e, S. Bandiera ^f, A. Boglione ^g, P. Boland ^h, S. Bolle ⁱ, Ø. Bruland ^j, A. Brunello ^k, P. Bruzzi ^l, D. Campanacci ^m, F. Cananzi ⁿ, R. Capanna ^o, R. Casadei ^p, A. Cordoba ^q, C. Court ^r, A.P. Dei Tos ^{s,t}, T.F. DeLaney ^u, A. De Paoli ^v, T.M. De Pas ^w, A. Desai ^x, L. Di Brina ^y, D.M. Donati ^p, N. Fabbri ^h, M.R. Fiore ^z, A. Frezza ^c, M. Gambarotti ^{aa}, A. Gasbarrini ^f, P. Georg ^b, G. Grignani ^{ab}, N. Hindi ^{ac}, E.B. Hug ^b, R. Jones ^{ad}, A. Kawai ^{ae}, A.D. Krol ^{af}, F. Le Grange ^{ag}, A. Luzzati ^{ah}, G. Marquina ^{ai}, J.A. Martin-Benlloch ^{aj}, K. Mazzocco ^{ak}, F. Navarra ^v, P. Navarra ^y, P.D. Parchi ^o, S. Patel ^{al}, E. Pennacchioli ^{am}, M.G. Petrongari ^{an}, P. Picci ^{ao}, R. Pollock ^{ap}, L. Porcu ^{aq}, V. Quagliuolo ^o, C. Sangalli ^{ar}, S. Scheipl ^{as}, G.M. Scotto ^{ai}, M. Spalek ^{at}, T. Steinmeier ^{au}, B. Timmermann ^{av}, A. Trama ^{aw}, M. Uhl ^{ax}, C. Valverde ^{ay}, P.P. Varga ^{az}, R. Verges ^{ba}, D.C. Weber ^{bb}, C. Zoccali ^{bc}, P.G. Casali ^{c, bd}, J. Sommer ^{be}, A. Gronchi ^a

^a Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

^b MedAustron Ion Therapy Center, Wiener Neustadt, Austria

^c Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy

^d Department of Orthopaedic Surgery, Saitama Medical Center, Jichi Medical University, Saitama, Japan

^e General Surgery III Department and Liver Transplant Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain

^f Department of Oncologic and Degenerative Spine Surgery, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy

^g Medical Oncology Unit, Ospedale Humanitas, Gradenigo, Torino, Italy

^h Orthopedic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, USA

ⁱ Département de Radiothérapie, Gustave-Roussy Cancer Campus, Villejuif, France

^j University of Oslo, Institute for Clinical Medicine and Department of Oncology, Oslo University Hospital-Norwegian Radium Hospital, Oslo, Norway

^k Department of Clinical and Experimental Oncology, Medical Oncology 1st Unit, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy

^l Dipartimento di Epidemiologia Clinica, IRCCS, AOU San Martino - IST, Genova, Italy

^m Department of Orthopedic Oncology, Azienda Ospedaliero Universitaria Careggi, Firenze, Toscana, Italy

ⁿ Surgical Oncology Unit - Humanitas Clinical and Research Center, Rozzano, Italy

^o 1st Orthopedic Division of Pisa University, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy

^p Department of Orthopedics, Istituto Ortopedico Rizzoli, University of Bologna, Bologna, Italy

^q Department of Radiotherapy, Oscar Lambret Comprehensive Cancer Center, Lille, France

^r Orthopaedic and Traumatology Department, Spine and Tumor Unit, Bicêtre University Hospital, AP-HP Paris, Univ. Paris-Sud Orsay, France

^s Department of Pathology and Molecular Genetics, Treviso General Hospital, Treviso, Italy

^t Department of Medicine, University of Padova School of Medicine, Padova, Italy

^u Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA

^v Department of Radiation Oncology, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy

^w Division of Medical Oncology for Melanoma & Sarcoma, IEO, European Institute of Oncology IRCCS, Milan, Italy

^x Department of Sarcoma and General Surgery, Midlands Abdominal and Retroperitoneal Sarcoma Unit, University Hospital Birmingham, NHS Foundation Trust, Birmingham, UK

^y Radiotherapy and Radiosurgery, Humanitas Clinical and Research Center, Rozzano, Milano, Italy

^z Radiotherapy Unit, National Center of Oncological Hadrontherapy (CNAO) Pavia, Italy

^{aa} Department of Pathology, IRCCS Rizzoli Orthopaedic Institute, Bologna, Italy

^{ab} Medical Oncology-Sarcoma Unit, Istituto di Candiolo-Fondazione del Piemonte per L'Oncologia, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Candiolo, Italy

^{ac} Instituto de Biomedicina (IBIS), Medical Oncology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain

^{ad} Royal Marsden Hospital and Institute of Cancer Research, London, UK

^{ae} Department of Musculoskeletal Oncology, National Cancer Center, Tokyo, Japan

^{af} Department of Radiation Oncology, Leiden University Medical Center, Leiden, the Netherlands

^{ag} University College London Hospitals NHS Foundation Trust and the London Sarcoma Service, UK

^{ah} Centro di Chirurgia Ortopedica Oncologica e Ricostruttiva del Rachide, IRCCS Istituto Ortopedico Galeazzi, Milano, Italy

^{ai} Department of Medical Oncology, Hospital Clinico San Carlos, Madrid, Spain

* Corresponding author. Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori Via Giacomo Venezian 1, 20133, Milan, Italy.

E-mail address: stefano.radaelli@istitutotumori.mi.it (S. Radaelli).

^{aj} Department of Orthopaedic Surgery, Hospital Clinico Universitario de Valencia, Valencia, Spain

^{ak} Applied Research Division for Cognitive and Psychological Science, European Institute of Oncology, Department of Oncology and Hemato-Oncology, University of Milan, Milano, Lombardia, Italy

^{al} Department of Sarcoma Medical Oncology, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, USA

^{am} Division of Melanoma, Soft Tissue Sarcomas and Rare Tumors, European Institute of Oncology, Milan, Italy

^{an} Department of Radiation Oncology, Regina Elena National Cancer Institute, Rome, Italy

^{ao} Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy

^{ap} Royal National Orthopaedic Hospital NHS Trust, Brockley Hill, Stanmore, Middlesex, UK

^{aq} Laboratory of Methodology for Clinical Research, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Italy

^{as} Department of Radiation Therapy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

^{at} Department of Orthopaedics and Trauma, Medical University of Graz, Graz, Austria

^{au} Department of Radiotherapy I, Maria Skłodowska-Curie Institute-Oncology Center, Warsaw, Poland

^{av} Department of Particle Therapy, University Hospital Essen, West German Proton Therapy Centre Essen (WPE), West German Cancer Center (WTZ), Germany

^{aw} Department of Particle Therapy, University Hospital Essen, West German Proton Therapy Centre Essen (WPE), West German Cancer Center (WTZ), German Cancer Consortium (DKTK), Germany

^{ax} Evaluative Epidemiology Unit, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy

^{ay} Department of Radiation Oncology, University of Heidelberg, Heidelberg, Germany

^{az} Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain

^{ba} National Center for Spinal Disorders, Budapest, Hungary

^{bb} Radiation Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain

^{bc} Centre for Proton Therapy, Paul Scherrer Institut, Villigen PSI, Switzerland

^{bd} Orthopedic Oncology Unit, Department of Experimental Clinical Oncology, Regina Elena National Cancer Institute, Rome, Italy

^{be} Department of Medical Oncology and Haemato-Oncology, University of Milan, Milan, Italy

^{bf} Chordoma Foundation, Durham, NC, USA

ARTICLE INFO

Article history:

Received 31 March 2020

Accepted 15 April 2020

Available online 27 April 2020

Keywords:

Sacral chordoma

Surgical margins

Surgery

Radiation therapy

ABSTRACT

Objective: Aim of the manuscript is to discuss how to improve margins in sacral chordoma.

Background: Chordoma is a rare neoplasm, arising in half cases from the sacrum, with reported local failure in >50% after surgery.

Methods: A multidisciplinary meeting of the “Chordoma Global Consensus Group” was held in Milan in 2017, focusing on challenges in defining and achieving optimal margins in chordoma with respect to surgery, definitive particle radiation therapy (RT) and medical therapies. This review aims to report on the outcome of the consensus meeting and to provide a summary of the most recent evidence in this field. Possible new ways forward, including on-going international clinical studies, are discussed.

Results: En-bloc tumor-sacrum resection is the cornerstone of treatment of primary sacral chordoma, aiming to achieve negative microscopic margins. Radical definitive particle therapy seems to offer a similar outcome compared to surgery, although confirmation in comparative trials is lacking; besides there is still a certain degree of technical variability across institutions, corresponding to different fields of treatment and different tumor coverage. To address some of these questions, a prospective, randomized international study comparing surgery versus definitive high-dose RT is ongoing. Available data do not support the routine use of any medical therapy as (neo)adjuvant/cytoreductive treatment.

Conclusion: Given the significant influence of margins status on local control in patients with primary localized sacral chordoma, the clear definition of adequate margins and a standard local approach across institutions for both surgery and particle RT is vital for improving the management of these patients.

© 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Introduction

Chordoma is a rare mesenchymal neoplasm, accounting for 1.4% of primary bone tumors. The reported yearly incidence is approximately 0.08/100,000 people [1,2]. It affects predominantly the axial skeleton, mostly the mobile spine and the sacrum in the older age group [3].

Although typically slow-growing, chordoma is characterised by local aggressiveness, with worldwide reported long-term local recurrence free survival rate less than 50% [4]. Local control is therefore undoubtedly a critical component in the cure of chordoma patients who usually die of local-regional disease.

This manuscript has been developed as part of a consensus meeting of the “Chordoma Global Consensus Group”, held in Milan

in September 2017. This group, consisting of multidisciplinary chordoma experts from both sides of the Atlantic and patients' advocates, has already attempted to define the best approach for managing primary and locally recurrent chordoma at all sites [4,5]. The 2017 meeting focused on the importance of margins in the treatment of this disease. A discussion of the current challenges in achieving optimal margins in sacral chordoma and of possible solutions was carried out.

This review reports on the outcome of the consensus meeting and provides a summary of the most recent evidence in this field.

Shaping surgical margins

Surgical margin status is the most important prognostic factor in sacral chordoma patients undergoing surgery [Table 1] [6–13]. En-bloc tumor-sacrum resection is the cornerstone of treatment of both primary and recurrent localized disease. Regardless of the

¹ contributed equally.

Table 1

Series of sacral chordoma patients reporting oncologic outcome according to the adequacy of surgical margins. *Data extrapolated from KM curves on available information.

Series	Year	No. Pts	Median FU (years)	Margin status %	R0				R1			
					5-year OS	5-year LR	10-year OS	10-year LR	5-year OS	5-year LR	10-year OS	10-year LR
Bergh P.	2000	30	8.1	R0 = 70 R1 = 14 R2 = 16	90%*	10%*	95%*	76%*	50%*	50%*	100%*	100%*
Fuchs B.	2005	52	7.8	R0 = 21 R1/R2 = 31	100%*	5%	100%*	—	25%*	71%	15%*	—
Kayani B.	2015	58	3.8	R0 = 48 R1 = 42 R2 = 10	85%*	36%	38%*	—	50%*	79%	13%*	—
Angelini A.	2015	71	9.5	R0 = 77% R1 = 23%	—	28%*	—	40%*	—	55%*	—	55%*
Ji T.	2017	115	4.9	R0 = 67 R1/R2 = 33	86%	32%	—	—	67%	74%	—	—
Radaelli S.	2016	99	8.7	R0 = 47 R1 = 43 R2 = 10	95%	18%	71%	31%	95%	38%	62%	58%
Yang Y.	2017	157	4.6	R0 = 21 R1 = 39 R2 = 40	—	17%	—	—	—	43%	—	—
Colangeli S.	2018	33	4.4	R0 = 52 R1 = 42 R2 = 6	—	10%*	—	10%*	—	100%*	—	100%*

approach used, the final goal is to achieve a wide local excision with negative microscopic margins [4,5,14].

Several retrospective analyses demonstrated the negative prognostic impact of positive microscopic margins on the outcome of sacral chordoma. However, even in patients where resection is microscopically complete, loco-regional relapses are seen in >50% of cases. Recurrences may occur late and only a minority of patients are disease-free at 15 years [4,5].

Resection margins

The anatomical conditions of the sacro-pelvic region represent a major constraint to achieve local control in sacral chordoma. Therefore, the goal of a radical resection may be challenging, potentially requiring the sacrifice of important structures resulting in permanent, life-changing functional sequelae, while simultaneously increasing the chance of perioperative complications [15].

Furthermore, due to its gelatinous consistency, multi-lobulated morphology and possibly its underlying biology, chordoma exhibits a particular tendency for loco-regional spread with a typical infiltrative growth pattern which follows the path of least anatomical resistance.

The neoplastic invasion of the surrounding posterior pelvic musculature represents a critical challenge for any sacral chordoma surgical approach; particularly in larger tumors, the best chance of obtaining adequate **lateral margins** strictly correlates with the extent of the muscular resection: both gluteus maximus and piriform muscles must be resected down to the posterior aspect of the iliac wings towards the greater sciatic notch. The superior gluteal vessels emerge at this point and must either be preserved or carefully ligated.

Additional important sites at risk of marginal margins are the sacrospinous and sacrotuberous ligaments. At this level, the neoplastic cells may invade these broad and thick fibers down to their bone insertion. In order to minimize the chance of neoplastic contamination of the **postero-inferior margin**, both sacrospinous and sacrotuberous ligaments, must be transected by means of an osteotome taking a fragment of ischial bone en-bloc with the ligaments.

A further major intraoperative concern is the protection of intrapelvic visceral and vascular structures. Particularly in large or proximally located tumors, the rectum may be displaced anteriorly, along with the common iliac vessels while the hypogastric arteries and veins may be encased within the neoplastic mass. This is potentially the most difficult part of the dissection: the mesorectum is a loose layer of adipo-lymphatic tissue, not always sufficient to provide a solid barrier against tumor spread. In addition, the surgical dissection aiming to separate the rectum from the tumor may increase the risk of tumor spillage. Neoplastic invasion of the posterior rectal wall is uncommon but if present, requires extended bowel resection and a colostomy (Fig. 1). When the rectum is only displaced anteriorly by the sacral chordoma, without infiltration, the surgical dissection may be carried out leaving the whole mesorectum on the specimen with the posterior rectal wall exposed. Thus, the tumor is kept entirely covered achieving an appropriate **anterior margin** (Fig. 2).

Similar to the bowel resection, management of vascular encasement requires an anterior abdominal approach. Careful preparation of the common iliac vessels, prophylactically ligating the ilio-lumbar vessels and the ischiatic/gluteal branches of the hypogastric arteries and veins, is carried out in order to reduce the blood supply to the tumor and the sacrum. This is considered the safest approach to minimize the risk of intra and post-operative blood loss.

The need to perform vascular replacement is uncommon; uni-lateral or bilateral internal iliac vessels ligation, however, may be required and carried out without complications.




Fig. 1. Neoplastic invasion of the posterior rectal wall. The tumor is therefore resected en-bloc with the sacrum and the rectum.




Fig. 2. The rectum is displaced anteriorly, without being infiltrated, by the sacral chordoma. The surgical dissection may be carried out leaving the whole mesorectum on the specimen with the posterior rectal wall exposed. Thus, the tumor is kept entirely covered achieving an appropriate anterior resection margin.

The wide surgical approach required in sacral chordoma directly impacts on the postoperative functional outcome, mostly secondary to damage to the sacral and pudendal plexus.

To some extent, neurological impairment is predictable as it is related to the level of the sacral nerve roots resection, which in turn depends on tumor size and location. Preservation of the more proximal nerve roots is critical to limit the neurological sequelae. When bilateral S3 roots are preserved, normal bladder and bowel function are usually maintained; when only one of the S3 roots is preserved there is a chance of urinary and bowel sphincter disorders (acute urinary retention and/or fecal incontinence, sexual impotence). When only bilateral S2 roots are preserved, urinary and bowel sphincter disorders inevitably occur, albeit potentially recovering in up to 40% of patients. If only the S1 roots are spared, permanent fecal and urinary dysfunction are to be expected while the movement of the leg and foot is usually maintained. The loss of S1 nerve roots is accompanied by motor dysfunction in the lower limbs, predominantly regarding the feet [16].

The resection of the whole sacral vertebra above the tumor as well as a meticulous assessment of the spinal canal and the paraspinal muscles is strongly recommended in order to achieve a clear **superior margin**. In some cases, small satellite nodules may be present slightly above the primary tumor but their presence should normally be detected by the initial radiological work-up. In addition, a careful intra-operative evaluation of the level of bone resection should rule out the presence of these skip lesions, which may eventually compromise the adequacy of the surgical result. Microsatellite nodules, generally below the resolution of radiological imaging, may also occur and are associated with a higher risk of local recurrence [17].

Once the sacrum is disconnected bilaterally and the ano-coccygeal ligament divided, careful manual palpation will identify the true extent of the tumor and space for the sacral transection can be created by blunt finger dissection.

A transverse side-to-side osteotomy is performed with an osteotome or saw at the sacral level usually chosen on the preoperative scan and then confirmed during the operation. Computer-assisted navigation may be of help to confirm the tumor level and to identify nerve roots and bone margins bilaterally. Orthopedic pins may be also superficially fixed on the bone, 2–3 cm away from the macroscopic tumor, in order to locate the line of the osteotomy and to ensure a tumor-free margin [18]. The whole specimen is therefore removed ‘en-bloc’ with the overlying skin including the biopsy track.

Reconstructive techniques

If the resection includes S1 (total sacrectomy), the pelvic skeleton loses its stability and spino-pelvic fixation is recommended, although some authors suggest no reconstruction also in this case,

leaving the lumbar spine collapsing into the pelvis [19,20]. The most commonly employed option for reconstruction of the pelvic ring uses a sacral bar to fix the two iliac bones one to each other and spino-pelvic fixation by spine reconstruction devices. Autologous bone graft from the iliac bone and/or one or both autogenous or allogenic fibulas may be useful to promote the bony union and increase the strength of the reconstruction [21,22].

In order to prevent any posterior bowel herniation, an artificial mesh can be placed behind the rectum. According to the extent of the skin/soft tissue defect, different reconstructive options are available. The use of local flaps, such as unilateral or bilateral gluteus muscle sliding flaps, is the preferred option. These cannot be used where the superior gluteal vessels have been ligated or the defect is very large and a rectus abdominis pedicled flap or a reverse rotational flap based on perforators from the posterior intercostal and lumbar vessels or a latissimus dorsi muscle free flap, may be considered [23–25].

Loco-regional relapse approach

The clinical presentation of loco-regional recurrence can be variable. Skip lesions adjacent to the surgical field and spreading towards the gluteal muscles or the pelvic cavity are unfavourable and usually associated with prior contaminated surgery.

Extensive local relapses may result in an exophytic mass ulcerating the skin, with a significant impairment in patients’ quality of life.

Post-relapse outcome is generally poor, even when a microscopically complete resection of the recurrence is carried out.

The goal of salvage re-resection with curative intent should be to achieve gross total resection and, where feasible, en-bloc resection with negative surgical margins. The best candidates for a complete re-resection are patients with limited disease, long disease-free interval, good performance status and a reasonable likelihood of acceptable morbidity from surgery [4,26].

Planning radiation margins

Large series of primary sacral chordoma patients treated with either surgery or radical definitive particle therapy have been published, showing similar long-term outcome with both modalities (Table 2) [5,11,27–35]. The “sandwich” approach with preoperative radiation therapy (RT), surgery and postoperative-RT is of great interest, but it has been used so far in selected institutions [36]. Ten-year local control is usually not >50%, with only one series reporting a 8-year local control of 85% [37,38].

Dose

Proton therapy (and mixed photon/proton radiotherapy) has a low linear energy transfer (LET), therefore the classical radiobiological concepts apply. Dose per fraction used with low LET radiation is 1.8–2 Gy (Relative Biological Effect-RBE). Total dose to macroscopic disease should be at least 74 Gy RBE and even >77 Gy (RBE) have been employed [39,40].

Carbon ion is a high LET radiation and therefore less sensitive to fractionation. Moderately hypo-fractionated schedules have been employed with dose per fraction of 4–4.4 Gy (RBE) and total dose of 64–70.4 Gy (RBE) in NIRS [27]. Dose per fraction of 3 Gy (RBE) and total dose of 66 Gy (RBE) have been used in the German experience [33].

The radiobiological model used in Japan and Europe to calculate the RBE is different. In the attempt to reproduce the Japanese results, the nominal RBE weighted prescription doses should be increased by about 10%, and therefore the dose per fraction employed in Italy in CNAO was 4.4–4.8 Gy (RBE) to a total dose of 70.4–76.8 Gy (RBE) [41–43].

Table 2

Comparison of oncologic outcomes for sacral chordoma treated with definitive heavy-particles RT. C = carbon ion; P = proton; N = neutron; IMRT = intensity modulated radiation therapy.

Series	Year	No. Pts	Median FU (years)	Therapy	5-year OS	10-year OS	5-year LR	10-year LR
Breteau N.	1998	13	4	N	61% (4yr)	—	44% (4yr)	—
Nishida Y.	2011	7	4.1	C	53%	—	0%	—
McDonald MW.	2013	16	1.9	P	80% (2 yr)	—	15% (2 yr)	—
Mima M.	2014	23	3.2	C or P	83% (3yr)	—	6% (3 yr)	—
Uhl M.	2015	56	2.1	C ± IMRT	52%	—	21%	—
Imai R.	2016	188	5	C	81%	67%	19%	50%
Kabolizadeh P.	2017	40	4.2	P ± IMRT	82%	—	15%	—
Youn SH.	2018	58	3.5	P	88%	—	12%	—
Aibe N.	2018	23	3.1	P	10% (3yr)	—	7% (3yr)	—

High doses are recommended in cases of gross residual disease. In cases of macroscopically clear resection with a microscopically involved (R1) margin, carbon ions will not be employed but instead low LET dose at reduced levels up to 70 Gy (RBE). In cases of R2 resection some authors recommend limiting the dose to the tumor bed to 70 Gy (RBE) and boosting the residual disease to 74–77 Gy (RBE) [37].

If postoperative RT is given after R0 resection the same dose of at least 70 Gy (RBE) should be applied to the tumor bed.

In sandwich treatment with low LET radiation, 19.8–50.4 Gy (RBE) with conventional fractionation should be applied preoperatively.

The authors agree that a wider volume should be treated to a lower dose. With low LET and standard fractionation, this lower dose for the area at risk of microscopic infiltration is set at 50–54 Gy (RBE). With carbon ion at 4.4–4.8 Gy (RBE) per fraction the low-dose is set at 39.6–43.2 Gy (RBE) in 9 fractions. Dose homogeneity, details about prescription point or dose volume histogram (DVH) point and acceptable target coverage are quite well established in proton beam therapy and should follow the recommendation of ICRU report 78. The uncertainty in carbon ion RBE is typically much larger (15%–20%) than the usual ICRU requirement of dose homogeneity (+5%). In the authors opinion the most relevant topic is not dose homogeneity but target volume coverage, especially in case of radical treatment where over conservative constraints on the rectum may lead to significant under-dosage on the macroscopic tumor. It would be advisable that constraints were given in terms of absolute rather than relative volume and the dose to 1–2 ml were considered beside the near minimum dose.

Volume

Defining the clinical target volume (CTV) is intrinsically a probabilistic procedure. There is a *de facto* consensus in radiation oncology to include in the CTV areas with a risk of microscopic tumor involvement higher than 10%. In the chordoma series currently available, the CTV contouring strategy is described only briefly and there is still variability across institutions. In a large series of 188 patients treated at NIRS, the CTV is obtained expanding the gross tumor volume (GTV) with a geometric margin of 5 mm. This geometrical expansion is edited to avoid overlap with rectum or bowel [27]. This same approach has been followed in other Japanese and in German facilities [32,33]. The results from the NIRS show a 5- and 10-year local control rate of 77.2% and 52.0% respectively. At MGH, a margin of 1.5 cm around extraosseous tumor was employed and specific care was given to the risk of infiltration along the glutei and piriform muscles. One whole vertebral body cranial and caudal to the gross disease was included and all scar and all stabilization devices were also contoured as areas at risk for the low-dose volume. In the MGH study, the volumes were modified to avoid overlap with intra-peritoneal organs. An initial attempt to standardize and harmonize

the contouring strategy for sacral chordoma has been carried out in the framework of the SACRO trial - Sacral Chordoma: a Randomized & Observational study on surgery versus definitive radiation therapy in primary localized disease (see below). Based on this initial consensus, general recommendations for extended target volume contouring are given below.

GTV

The macroscopic tumor can be easily detected with CT and MR scan and therefore GTV contouring is typically straightforward. T2 weighted images show better contrast between chordoma and surrounding bone and muscles. Satellite nodule(s) should be included in the GTV (Fig. 3).

Low-dose CTV

Cranial margin. One or two (one for preoperative radiation) vertebral bodies rostral to the GTV should be included. For sacral tumors, it is almost never necessary to include L4. If the GTV is involving S2 but not S1, the CTV should not extend to L5. For tumors lower than S2, two sacral levels above should be included. In case of sacral canal invasion, the whole thickness of the sacrum must be included in the CTV. However, if the tumor grows anteriorly and has a cranial tail along the pre-sacral fascia, the cranial expansion can be limited to the anterior part of the sacrum.

Caudal margin. For postoperative radiation, the whole sacrum and coccyx should be included. For selected case of S1 or S2 tumors with minimal bone erosion it may be acceptable to limit the caudal border to 1–2 levels below. For preoperative radiation, a single vertebral level distal to the caudal extent of tumor seems enough.

Lateral margin. Both piriform muscles should be entirely included in the CTV. The CTV should extend to the bony lamina. In selected cases (e.g. small unilateral tumors in S1–S2 confined to the bone) it may be possible not to include both piriform muscles entirely. The degree of lateral extension into the gluteal muscles is debatable. If the GTV extends laterally and or caudally outside the sacrum and the muscles are clearly infiltrated all areas where edema or enlarged blood vessels are present (as detectable with CT and T2 MR sequences) should be included in low-dose CTV. Nevertheless, at least 1.5 cm margin of radiologically normal muscle. If satellite nodules are detectable in the glutei, the low-dose CTV should include them all in a single volume. For preoperative radiation, these have been reported with high rates of local tumor control [17,38]. At all sacral levels where there is macroscopic tumor the lateral margin should extend to the sacroiliac joints.

Posterior margin. If the tumor infiltrates the subcutaneous soft tissues, CTV should extend to the skin. If posterior bony wall of the sacrum is intact it is not necessary to include the subcutaneous tissue in the CTV.




Fig. 3. GTV and CTV contouring of sacral chordoma by CT/MRI scan **a)** one or two vertebral bodies rostral to the GTV and the whole sacrum caudally should be included **b)** sacroiliac joint contoured within the CTV **c)** biopsy tract or surgical scars should be included in the low-dose CTV **d)** the degree of lateral extension into the gluteal muscles is debatable albeit at least 1.5 cm margin of radiologically normal muscle should be included in the low dose CTV **e)** both piriform muscles should be entirely included in the CTV.

Anterior margin. The anterior margin can coincide with the GTV and with the anterior surface of the sacrum. Nerve roots exiting from the foramina should also be included. The CTV should not include the rectal wall, the peritoneum or the ileo-psoas muscles (unless clearly infiltrated). If a surgical procedure has been performed to displace the rectum/bowel from the high-dose volume, it is possible, depending on the operation performed, that microscopic tumor is displaced together with the rectal wall. It is therefore recommended that low-dose CTV includes the spacer if the presacral and/or mesorectal space has been violated. It is not necessary to include the spacer in the CTV if it has been inserted with an anterior approach without opening the pelvic peritoneum or if preoperative radiation has been given.

Biopsy-tract and surgical scar. Biopsy tract or surgical scars should be included in the low-dose CTV. When passive beam is used and there is a concern regarding skin toxicity the biopsy-tract contour can be reduced to avoid overlap with the skin.

Surgical devices. In case of postoperative irradiation, all implanted stabilization devices are to be considered at risk of tumor seeding and should be included in the CTV if this can be done with acceptable morbidity.

High-dose CTV

High-dose CTV should be a geometric expansion of GTV enlarged by 5–10 mm and not extending outside the low-dose CTV.

Toxicity

The most important toxicities related to high dose particle therapy are sacral neuropathy and sacral fractures.

For sacral neuropathy, a dose threshold around 74 Gy for conventional fractionation and 70 Gy (RBE) for hypo fractionation seems to exist.

Sacral insufficiency fractures were reported in 47% of patients treated at MGH with combined surgery and proton therapy, in 52% of patients treated with carbon ion radiotherapy without surgery and in 33% of patients treated with only proton therapy [44,45]. The extent of surgical resection, the amount of irradiated bone and the

maximum dose may be relevant in determining the risk of fracture [46].

Approaching margins medically

Medical therapies are considered in advanced patients with symptoms, where there is a clear evidence of progressive disease or both. Given the chemo-resistance of conventional chordoma and the low dimensional response rate observed with targeted agents (2–3%) [47], there is no clear indication for a (neo)-adjuvant treatment in this disease, even when tumor shrinkage would be beneficial. Similarly, outside clinical studies, the low expected dimensional response rate as well as the inability of medical therapies to impact upon the complexity of surgery or the extent of RT, argue against the use of any of these agents prior to surgery, RT or in association with radiation [1]. Nonetheless, the results of available studies (all in the setting of advanced disease), leave medical therapy as an option to be discussed with patients deemed unfit for surgery or high-dose RT, or unwilling to undergo local treatments due to the associated morbidity [47,48].

Future perspectives

Currently, patients presenting with primary, localized sacral chordoma are often treated inconsistently.

The area affected by the highest variability is local treatment, as the approach spans from wide en-bloc resection (with or without adjuvant RT) to definitive RT (with or without pre-RT surgical debulking).

Since equipoise exists between these two approaches, a prospective international randomized clinical study (called “SACRO”) comparing surgery (plus/minus postoperative RT) with definitive high-dose RT has recently started recruiting patients to assess both relapse-free survival and quality of life (NCT02986516).

This trial will be the first formal, prospective comparison between the two local treatments in chordoma. In order to accommodate the difficult clinical decision-making as well as encouraging patient participation, an observational arm was included into the study, paralleling the randomized component. Patients will either be randomized or allocated to their preferred

treatment and prospectively observed. A Bayesian approach has been selected, thus valuing prior probabilities and continuously updating probability distributions of outcomes as long as new patients are evaluated.

In conclusion, the rate of local recurrence in primary localized sacral chordoma is still high and only very slow progress is being made. A large proportion of patients, in fact, still die of local disease and for those who do not relapse, quality of life is often poor as a result of surgical morbidity.

Much work still needs to be done in order to improve the state of the art in chordoma. Only a collaborative effort among major reference centers across the world may allow performing large clinical trials.

Funding

None declared.

Declaration of competing interest

The authors have declared no conflicts of interest.

Acknowledgements

None.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ejso.2020.04.028>.

References

- [1] Smoll NR, Gautschi OP, Radovanovic I, Schaller K K, Weber DC. Incidence and relative survival of chordomas: the standardized mortality ratio and the impact of chordomas on a population. *Cancer Jun 1 2013*;119(11):2029–37.
- [2] Gatta G, Capocaccia R, Botta L, Mallone S, De Angelis R, Ardanaz E, et al. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study. *Lancet Oncol Aug 2017*;18(8):1022–39.
- [3] Lau CS, Mahendraraj K, Ward A, Chamberlain RS. Pediatric chordomas: a population-based clinical outcome study involving 86 patients from the surveillance, epidemiology, and end result (seer) database (1973–2011). *Pediatr Neurosurg 2016*;51(3):127–36.
- [4] Stacchiotti S, Gronchi A, Fossati P, Akiyama T, Alapetite C, Baumann M, et al. Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group. *Ann Oncol: Off J Eur Soc Med Oncol Jun 1 2017*;28(6):1230–42.
- [5] Stacchiotti S, Sommer J, Chordoma Global Consensus Group. Building a global consensus approach to chordoma: a position paper from the medical and patient community. *Lancet Oncol Feb 2015*;16(2):e71–83.
- [6] Bergh P, Kindblom LG, Gunterberg B, Remotti F, Ryd W, Meis-Kindblom JM. Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients. *Cancer May 1 2000*;88(9):2122–34.
- [7] Fuchs B, Dickey ID, Yaszemski MJ, Inwards CY, Sim FH. Operative management of sacral chordoma. *The Journal of bone and joint surgery (American Volume) Oct 2005*;87(10):2211–6.
- [8] Kayani B, Sewell MD, Tan KA, Hanna SA, Williams R, Pollock R, et al. Prognostic factors in the operative management of sacral chordomas. *World neurosurgery Nov 2015*;84(5):1354–61.
- [9] Angelini A, Pala E, Calabro T, Maraldi M, Ruggieri P. Prognostic factors in surgical resection of sacral chordoma. *J Surg Oncol Sep 2015*;112(4):344–51.
- [10] Ji T, Guo W, Yang R, Tang X, Wang Y, Huang L. What are the conditional survival and functional outcomes after surgical treatment of 115 patients with sacral chordoma? *Clin Orthop Relat Res Mar 2017*;475(3):620–30.
- [11] Radaelli S, Stacchiotti S, Ruggieri P, Donati D, Casali PG, Palmerini E, et al. Sacral chordoma: long-term outcome of a large series of patients surgically treated at two reference centers. *Spine Jun 2016*;41(12):1049–57.
- [12] Yang Y, Niu X, Li Y, Liu W, Xu H. Recurrence and survival factors analysis of 171 cases of sacral chordoma in a single institute. *Eur Spine J: Off Publ Eur Spinal Deform Soc Eur Sec Cerv Spine Res Soc Jul 2017*;26(7):1910–6.
- [13] Colangeli S, Muratori F, Bettini L, Frenos F, Totti F, D'Arienzo A, et al. Surgical treatment of sacral chordoma: en bloc resection with negative margins is a determinant of the long-term outcome. *Surg Technol Int Sep 11 2018*;33.
- [14] Varga PP, Szoverfi Z, Fisher CG, Boriani S, Gokaslan ZL, Dekutoski MB, et al. Surgical treatment of sacral chordoma: prognostic variables for local recurrence and overall survival. *Eur Spine J: Off Publ Eur Spine Soc Eur Spinal Deform Soc Eur Sec Cerv Spine Res Soc May 2015*;24(5):1092–101.
- [15] Zoccali C, Skoch J, Patel A, Walter CM, Maykowsky P, Baaj AA. The surgical neurovascular anatomy relating to partial and complete sacral and sacroiliac resections: a cadaveric, anatomic study. *Eur Spine J: Off Publ Eur Spine Soc Eur Spinal Deform Soc Eur Sec Cerv Spine Res Soc May 2015*;24(5):1109–13.
- [16] Zoccali C, Skoch J, Patel AS, Walter CM, Maykowsky P, Baaj AA. Residual neurological function after sacral root resection during en-bloc sacrectomy: a systematic review. *Eur Spine J: Off Publ Eur Spine Soc Eur Spinal Deform Soc Eur Sec Cerv Spine Res Soc Dec 2016*;25(12):3925–31.
- [17] Akiyama T, Ogura K, Gokita T, Tsukushi S, Iwata S, Nakamura T, et al. Analysis of the infiltrative features of chordoma: the relationship between micro-skip metastasis and postoperative outcomes. *Ann Surg Oncol Apr 2018*;25(4):912–9.
- [18] Asavamongkolkul A, Waikakul S. Wide resection of sacral chordoma via a posterior approach. *Int Orthop Mar 2012*;36(3):607–12.
- [19] Kiatisevi P, Piyaskulkaew C, Kunakornsawat S, Sukunthanak B. What are the functional outcomes after total sacrectomy without spinopelvic reconstruction? *Clin Orthop Relat Res Mar 2017*;475(3):643–55.
- [20] Ruggieri P, Angelini A, Ussia G, Montalti M, Mercuri M. Surgical margins and local control in resection of sacral chordomas. *Clin Orthop Relat Res Nov 2010*;468(11):2939–47.
- [21] Macki M, De la Garza-Ramos R, Murgatroyd AA, Mullinix KP, Sun X, Cunningham BW, et al. Comprehensive biomechanical analysis of three reconstruction techniques following total sacrectomy: an in vitro human cadaveric model. *J Neurosurg Spine Nov 2017*;27(5):570–7.
- [22] Guo W, Tang X, Zang J, Ji T. One-stage total en bloc sacrectomy: a novel technique and report of 9 cases. *Spine May 1 2013*;38(10):E626–31.
- [23] Kim JE, Pang J, Christensen JM, Coon D, Zadnik PL, Wolinsky JP, et al. Soft-tissue reconstruction after total en bloc sacrectomy. *J Neurosurg Spine Jun 2015*;22(6):571–81.
- [24] Reynolds JJ, Khundkar R, Boriani S, Williams R, Rhines LD, Kawahara N, et al. Soft tissue and bone defect management in total sacrectomy for primary sacral tumors: a systematic review with expert recommendations. *Spine Oct 15 2016*;41(Suppl 20):S199–204.
- [25] Kiiski J, Kuokkanen HO, Kaariainen M, Kaartinen IS, Pakarinen TK, Laitinen MK. Clinical results and quality of life after reconstruction following sacrectomy for primary bone malignancy. *J Plast Reconstr Aesthetic Surg: JPRAS Dec 2018*;71(12):1730–9.
- [26] Ailon T, Torabi R, Fisher CG, Rhines LD, Clarke MJ, Bettgowda C, et al. Management of locally recurrent chordoma of the mobile spine and sacrum: a systematic review. *Spine Oct 15 2016*;41(Suppl 20):S193–8.
- [27] Imai R, Kamada T, Araki N, Working Group for Bone and Soft Tissue Sarcoma. Carbon ion radiation therapy for unresectable sacral chordoma: an analysis of 188 cases. *Int J Radiat Oncol Biol Phys May 1 2016*;95(1):322–7.
- [28] Nishida Y, Kamada T, Imai R, Tsukushi S, Yamada Y, Sugiura H, et al. Clinical outcome of sacral chordoma with carbon ion radiotherapy compared with surgery. *Int J Radiat Oncol Biol Phys Jan 1 2011*;79(1):110–6.
- [29] McDonald MW, Linton OR, Shah MV. Proton therapy for reirradiation of progressive or recurrent chordoma. *Int J Radiat Oncol Biol Phys Dec 1 2013*;87(5):1107–14.
- [30] Youn SH, Cho KH, Kim JY, Ha B, Lim YK, Jeong JH, et al. Clinical outcome of proton therapy for patients with chordomas. *Radiation oncology journal Sep 2018*;36(3):182–91.
- [31] Breteau N, Demasure M, Lescrainier J, Sabbattier R, Michenet P. Sacrococcygeal chordomas: potential role of high LET therapy. *Recent Results Canc Res. Fortschritt der Krebsforschung. Progres dans les recherches sur le cancer 1998*;150:148–55.
- [32] Mima M, Demizu Y, Jin D, Hashimoto N, Takagi M, Terashima K, et al. Particle therapy using carbon ions or protons as a definitive therapy for patients with primary sacral chordoma. *Br J Radiol Jan 2014*;87(1033):20130512.
- [33] Uhl M, Welzel T, Jensen A, Ellerbrock M, Haberer T, Jäkel O, et al. Carbon ion beam treatment in patients with primary and recurrent sacrococcygeal chordoma. *Strahlenther Onkol: Organ der Deutschen Röntgengesellschaft Jul 2015*;191(7):597–603 [et al].
- [34] Kabolizadeh P, Chen YL, Liebsch N, Hornicek FJ, Schwab JH, Choy E, et al. Updated outcome and analysis of tumor response in mobile spine and sacral chordoma treated with definitive high-dose photon/proton radiation therapy. *Int J Radiat Oncol Biol Phys Feb 1 2017*;97(2):254–62.
- [35] Aibe N, Demizu Y, Sulaiman NS, Matsuo Y, Mima M, Nagano F, et al. Outcomes of patients with primary sacral chordoma treated with definitive proton beam therapy. *Int J Radiat Oncol Biol Phys Mar 15 2018*;100(4):972–9.
- [36] Rotondo RL, Folkert W, Liebsch NJ, Chen YL, Pedlow FX, Schwab JH, et al. High-dose proton-based radiation therapy in the management of spine chordomas: outcomes and clinicopathological prognostic factors. *J Neurosurg Spine Dec 2015*;23(6):788–97.
- [37] DeLaney TF, Liebsch NJ, Pedlow FX, Adams J, Dean S, Yeap BY, et al. Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. *Int J Radiat Oncol Biol Phys Jul 1 2009*;74(3):732–9.
- [38] DeLaney TF, Liebsch NJ, Pedlow FX, Adams J, Weyman EA, Yeap BY, et al. Long-term results of Phase II study of high dose photon/proton radiotherapy in the management of spine chordomas, chondrosarcomas, and other sarcomas. *J Surg Oncol Aug 2014*;110(2):115–22.
- [39] Park L, Delaney TF, Liebsch NJ, Hornicek FJ, Goldberg S, Mankin H, et al. Sacral

- chordomas: impact of high-dose proton/photon-beam radiation therapy combined with or without surgery for primary versus recurrent tumor. *Int J Radiat Oncol Biol Phys* Aug 1 2006;65(5):1514–21.
- [40] Staab A, Rutz HP, Ares C, Timmermann B, Schneider R, Bolsi A, et al. Spot-scanning-based proton therapy for extracranial chordoma. *Int J Radiat Oncol Biol Phys* Nov 15 2011;81(4):e489–96.
- [41] Fossati P, Molinelli S, Matsufuji N, Ciocca M, Mirandola A, Mairani A, et al. Dose prescription in carbon ion radiotherapy: a planning study to compare NIRS and LEM approaches with a clinically-oriented strategy. *Phys Med Biol* Nov 21 2012;57(22):7543–54.
- [42] Molinelli S, Magro G, Mairani A, Matsufuji N, Kanematsu N, Inaniwa T, et al. Dose prescription in carbon ion radiotherapy: how to compare two different RBE-weighted dose calculation systems. *Radiother Oncol : J Eur Soc Therapeut Radiol Oncol* Aug 2016;120(2):307–12.
- [43] Steinstrater O, Grun R, Scholz U, Friedrich T, Durante M, Scholz M. Mapping of RBE-weighted doses between HIMAC- and LEM-Based treatment planning systems for carbon ion therapy. *Int J Radiat Oncol Biol Phys* Nov 1 2012;84(3): 854–60.
- [44] Chen YL, Liebsch N, Kobayashi W, Goldberg S, Kirsch D, Calkins G, et al. Definitive high-dose photon/proton radiotherapy for unresected mobile spine and sacral chordomas. *Spine* Jul 1 2013;38(15):E930–6.
- [45] Bostel T, Nicolay NH, Welzel T, Bruckner T, Mattke M, Akbaba S, et al. Sacral insufficiency fractures after high-dose carbon-ion based radiotherapy of sacral chordomas. *Radiat Oncol* Aug 23 2018;13(1):154.
- [46] Osler P, Bredella MA, Hess KA, Janssen SJ, Park CJ, Chen YL, et al. Sacral insufficiency fractures are common after high-dose radiation for sacral chordomas treated with or without surgery. *Clin Orthop Relat Res* Mar 2016;474(3):766–72.
- [47] Lebellec L, Chauffert B, Blay JY, Le Cesne A, Chevreau C, Bompas E, et al. Advanced chordoma treated by first-line molecular targeted therapies: outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Francaise (ANOCEF). *Eur J Canc* Jul 2017;79:119–28.
- [48] Stacchiotti S, Morosi C, Lo Vullo S, Casale A, Palassini E, Frezza AM, et al. Imatinib and everolimus in patients with progressing advanced chordoma: a Phase 2 clinical study. *Cancer* 2018 Oct;15124(20):4056–63.